{"id":8735,"date":"2013-07-22T02:59:41","date_gmt":"2013-07-22T06:59:41","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=8735"},"modified":"2013-07-22T02:59:41","modified_gmt":"2013-07-22T06:59:41","slug":"biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735","title":{"rendered":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 07\/22\/2013 (wallstreetpr) &#8211;\u00a0The biotechnology business has always appealed to investors seeking the best home run investment. One niche within that business that looks balanced to augment deals with small molecule medicines used to cure illnesses. With hoards of money being invested into this section on a yearly basis, the stakes are high but so are the rewards. One stock, which seems close to appreciate in a statistically significant way, is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).<\/p>\n<p style=\"text-align: justify;\">A few reasons why shareholders should consider adding a position shortly are as follows &#8211;<\/p>\n<p style=\"text-align: justify;\"><b>Company Background<\/b><\/p>\n<p style=\"text-align: justify;\">BioCryst Pharmaceuticals devises, optimizes and builds up innovative small-molecule medicines, which block major enzymes involved in contagious and seditious illnesses. BioCryst makes use of revolutionary medicine plan that includes manifold scientific disciplines comprising biology, crystallography, therapeutic chemistry and computer modeling, with the aim to most professionally build up new healing candidates.<\/p>\n<p style=\"text-align: justify;\"><b>Corporate Plan<\/b><\/p>\n<p style=\"text-align: justify;\">BioCryst Pharmaceuticals designs drug applicants utilizing thorough knowledge of the arrangement of active places of targeted enzymes. The active site of an enzyme is the region in which a chemical or biological particle equips to start a biochemical reaction. Enzymes build perfect drug objectives as they intercede biochemical procedures along infection pathways, are relatively simple to clear up and have diminutive active sites. The company intends to permit or design chemical compounds, which will blend in the vigorous sites of enzymes and thus retard the succession of illness. Making use of this approach, the firm has effectively both accredited and designed product applicants for communicable and provocative illnesses.<\/p>\n<p style=\"text-align: justify;\">In addition, BioCryst Pharmaceuticals (NASDAQ:BCRX) got promoted by JMP Securities and bagged \u201coutperform\u201d ranking in a research note.<\/p>\n<p style=\"text-align: justify;\">BioCryst Pharmaceuticals (NASDAQ:BCRX) previously declared its earnings outcomes on May 7th. The firm registered an EPS of $0.09 for the quarterly period.<\/p>\n<p style=\"text-align: justify;\">It registered an income of $3.60 million for the same period.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 07\/22\/2013 (wallstreetpr) &#8211;\u00a0The biotechnology business has always appealed to investors seeking the best home run investment. One niche within that business that looks [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":8736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2868,2869],"stock_ticker":[],"class_list":["post-8735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-biocryst-pharmaceuticals-inc-nasdaqbcrx","tag-nasdaqbcrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 07\/22\/2013 (wallstreetpr) &#8211;\u00a0The biotechnology business has always appealed to investors seeking the best home run investment. One niche within that business that looks [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-07-22T06:59:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run\",\"datePublished\":\"2013-07-22T06:59:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\"},\"wordCount\":318,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg\",\"keywords\":[\"BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)\",\"NASDAQ:BCRX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\",\"name\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg\",\"datePublished\":\"2013-07-22T06:59:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735","og_locale":"en_US","og_type":"article","og_title":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run - Wall Street PR","og_description":"Boston, MA 07\/22\/2013 (wallstreetpr) &#8211;\u00a0The biotechnology business has always appealed to investors seeking the best home run investment. One niche within that business that looks [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-07-22T06:59:41+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run","datePublished":"2013-07-22T06:59:41+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735"},"wordCount":318,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg","keywords":["BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)","NASDAQ:BCRX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735","url":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735","name":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg","datePublished":"2013-07-22T06:59:41+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/07\/placebo-pills.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/biocryst-pharmaceuticals-inc-nasdaqbcrx-is-an-appealing-investment-for-long-run-8735#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is An Appealing Investment For Long Run"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/8735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=8735"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/8735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/8736"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=8735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=8735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=8735"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=8735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}